Loading cancer entity…
Loading cancer entity…
Clinical trials
62 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02180867 | Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery | completed | Phase 2 / Phase 3 | 140 | National Cancer Institute (NCI)NIH | 3 | Jun 17, 2026 | clinicaltrials |
| NCT03304678 | Discovery of Sirolimus Sensitive Biomarkers in Blood | completed | Phase 2 | 33 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Feb 18, 2026 |
| clinicaltrials |
| NCT03190174 | Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers | completed | Phase 1 / Phase 2 | 34 | Sarcoma Oncology Research Center, LLCOTHER | 1 | Feb 17, 2025 | clinicaltrials |
| NCT01353209 | Letrozole for Lymphangioleiomyomatosis(TRAIL) | completed | Phase 2 | 17 | University of CincinnatiOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT02494570 | A Phase 2 Study of Nab-sirolimus (ABI-009) in Patients With Advanced Malignant PEComa(AMPECT) | completed | Phase 2 | 34 | Aadi Bioscience, Inc.INDUSTRY | 1 | Apr 7, 2023 | clinicaltrials |
| NCT03253913 | Resveratrol and Sirolimus in Lymphangioleiomyomatosis Trial(RESULT) | completed | Phase 2 | 25 | University of CincinnatiOTHER | 1 | Feb 1, 2023 | clinicaltrials |
| NCT03062943 | A Study of Nintedanib for LymphAngioleioMyomatosis (LAM)(LAM) | completed | Phase 2 | 30 | IRCCS MultimedicaOTHER | 1 | Sep 28, 2022 | clinicaltrials |
| NCT00126672 | RAPAMYCIN FOR KIDNEY ANGIOMYOLIPOMAS | completed | Phase 2 | 36 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 25, 2022 | clinicaltrials |
| NCT02484664 | COLA: A Pilot Clinical Trial of COX-2 Inhibition in LAM and TSC(COLA) | completed | Phase 2 | 12 | Brigham and Women's HospitalOTHER | 1 | Jan 20, 2022 | clinicaltrials |
| NCT01059318 | A Study to Determine the Safety and Effectiveness of RAD001 (Everolimus) in Patients With Lymphangioleiomyomatosis | completed | Phase 2 | 24 | Novartis PharmaceuticalsINDUSTRY | 3 | Nov 19, 2020 | clinicaltrials |
| NCT02061397 | Safety of Simvastatin in LAM and TSC(SOS) | completed | Phase 1 / Phase 2 | 10 | University of PennsylvaniaOTHER | 1 | Aug 25, 2020 | clinicaltrials |
| NCT03131999 | LAM Pilot Study With Imatinib Mesylate(LAMP-1) | completed | Phase 1 / Phase 2 | 18 | Medical University of South CarolinaOTHER | 1 | Jun 16, 2020 | clinicaltrials |
| NCT00457964 | RAD001 Therapy of Angiomyolipomata in Patients With TS Complex and Sporadic LAM | completed | Phase 1 / Phase 2 | 36 | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Sep 25, 2013 | clinicaltrials |
| NCT00005906 | Treatment With Octreotide in Patients With Lymphangioleiomyomatosis | completed | Phase 2 | 4 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Apr 30, 2010 | clinicaltrials |
| NCT00457808 | Rapamycin Therapy for Patients With Tuberous Sclerosis Complex and Sporadic LAM | completed | Phase 2 | 25 | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Apr 9, 2007 | clinicaltrials |
Data updated 22 days agoSource updated Jun 17, 2026source: clinicaltrials